Mobiele menu

A novel high-resolution SPECT system to provide new insights into brain functions

Projectomschrijving

SPECT is een beeldvormende techniek waarmee op moleculair niveau hersenonderzoek uitgevoerd kan worden in de levende mens. Dit voorstel voorziet in een nieuw SPECT-systeem (met hoge plaatsresolutie) om tot nieuwe inzichten in het (dys)functioneren van de hersenen te komen. 

Producten

Titel: Serotonin transporter occupancy by the SSRI citalopram predicts default-mode network connectivity
Auteur: Schrantee, Anouk, Lucassen, Paul J, Booij, Jan, Reneman, Liesbeth
Magazine: European Neuropsychopharmacology
Titel: Performance evaluation of a novel brain-dedicated SPECT system
Auteur: Stam, M. K., Verwer, E. E., Booij, J., Adriaanse, S. M., de Bruin, C. M., de Wit, T. C.
Magazine: EJNMMI Phys
Titel: Timing of caloric intake during weight loss differentially affects striatal dopamine transporter and thalamic serotonin transporter binding
Auteur: Versteeg, Ruth I., Schrantee, Anouk, Adriaanse, Sofie M., Unmehopa, Unga A., Booij, Jan, Reneman, Liesbeth, Fliers, Eric, la Fleur, Susanne E., Serlie, Mireille J.
Magazine: FASEB Journal
Titel: Relationship between muscarinic M 1 receptor binding and cognition in medication-free subjects with psychosis
Auteur: Bakker, Geor, Vingerhoets, Claudia, Boucherie, Daphne, Caan, Matthan, Bloemen, Oswald, Eersels, Jos, Booij, Jan, van Amelsvoort, Thérèse
Magazine: Neuroimage Clinical
Titel: Clinical evaluation of [123I]FP-CIT SPECT scans on the novel brain-dedicated InSPira HD SPECT system: a head-to-head comparison
Auteur: Adriaanse, Sofie M., de Wit, Tim C., Stam, Mette, Verwer, Eline, de Bruin, Kora M., Booij, Jan
Magazine: EJNMMI Research

Verslagen


Samenvatting van de aanvraag

Single photon emission computed tomography (SPECT) is an imaging technique which enables the visualisation and quantification of specific molecules in the living brain. This tool is important in research and in routine clinical studies. In the Netherlands, one brain-dedicated SPECT system (Neurofocus) is available for studies in non-human primates and humans. This system was installed in Amsterdam, and many scientific studies, particularly on neuroreceptors, have been successfully performed. This success is reflected in a lot of peer-reviewed publications, particularly on the evaluation of new tracers and on clinical studies. The successfulness of our research is also reflected in the spin-off of our activities; i.e., a major role in the registration trials of SPECT tracers for dopamine D2/3 receptors ([123I]IBZM) and dopamine transporters ([123I]FP-CIT). Particularly, [123I]FP-CIT is now licensed in Europe and the USA, and is used to detect or exclude nigostriatal dopaminergic cell loss in patients presenting with symptoms suggestive of dopaminergic neurodegeneration (e.g., Parkinson’s disease). The Neurofocus system was pivotal for the success of these studies, but this system is inadequate to fulfil the present demands for providing new insights into brain functions in health and disease. For this purpose, we need to image receptors in smaller brain areas, to perform faster dynamic studies, and to improve the quantification of brain SPECT studies. To achieve this, a SPECT system with higher sensitivity (efficiency to detect photons) and spatial resolution is needed. Recently, a novel brain SPECT scanner has been developed (called inSPira). This system offers the potential to perform studies with high sensitivity and spatial resolution (up to 3 mm). It is now in the early release phase (FDA approved; until now only 4 prototypes are installed in the USA). We request funds to acquire this system, which will be the first-of-its-kind in Europe. In the Netherlands there is a strong interest in this novel system to evaluate new SPECT tracers, as well as to perform clinical trials. In this project, we will first evaluate the performance characteristics of this new system and we will then evaluate the system’s clinical applicability. We anticipate that this system will be available for clinical studies within a timeframe of 2 years, and from then on will be accessible for research groups throughout the Netherlands to perform state-of-the-art brain SPECT studies in non-human primates as well as in humans. This investment is essential for the successful development and evaluation of novel brain SPECT tracers in the Netherlands, and will enhance our understanding of neuropsychiatric disorders. This strategy will lead to new insights into brain (dys)functions and will strengthen the leading position of Dutch groups in the field of brain SPECT imaging.

Onderwerpen

Kenmerken

Projectnummer:
91112002
Looptijd: 100%
Looptijd: 100 %
2012
2019
Onderdeel van programma:
Gerelateerde subsidieronde:
Projectleider en penvoerder:
Prof. dr. J. Booij
Verantwoordelijke organisatie:
Amsterdam UMC - locatie AMC